

Instance: composition-en-1cafc851e1f0aed5863b6a73ba46d0f7
InstanceOf: CompositionUvEpi
Title: "Composition for nubeqa Package Leaflet"
Description:  "Composition for nubeqa Package Leaflet"
Usage: #example

* identifier.system = ""

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mock)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - nubeqa"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  What is in this leaflet 
 
1. What NUBEQA is and what it is used for 
2. What you need to know before you take NUBEQA 
3. How to take NUBEQA 
4. Possible side effects 
5. How to store NUBEQA 
6. Contents of the pack and other information 
         </div>"""   
          

* section[=].section[+]
  * title =  "1. What nubeqa is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What nubeqa is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>NUBEQA contains the active substance darolutamide.<br />
It is used to treat adult men with prostate cancer that: 
- has not spread to other parts of the body and no longer responds to medical or surgical treatment 
that lowers testosterone (also called non-metastatic castration-resistant prostate cancer) 
- has spread to other parts of the body and responds to medical or surgical treatment that lowers 
testosterone (also called metastatic hormone-sensitive prostate cancer). </p>
<p>How NUBEQA works 
NUBEQA blocks the activity of male sex hormones called androgens, such as testosterone. By blocking 
these hormones, darolutamide stops prostate cancer cells from growing and dividing. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take nubeqa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take nubeqa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take NUBEQA if 
- you are allergic to darolutamide or any of the other ingredients of this medicine (listed in 
section 6) 
- you are a woman who is or may become pregnant. </p>
<p>Warnings and precautions 
Talk to your doctor or pharmacist before taking NUBEQA if 
- you have problems with your kidneys 
- you have problems with your liver 
- you have any heart conditions including heart rhythm problems or if you are using medicines 
for these conditions 
- you had a surgery to treat blood vessel conditions. </p>
<p>Taking this medicine may affect your liver tests. If your blood tests show abnormal results of your 
liver function, your doctor may decide to stop treatment permanently. </p>
<p>Children and adolescents 
This medicine is not for use in children and adolescents under 18 years. Prostate cancer does not occur 
in this age group. </p>
<p>Other medicines and NUBEQA 
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. </p>
<p>The following medicines may influence the effect of NUBEQA, or NUBEQA may influence the effect 
of these medicines to treat: 
- bacterial infections, such as rifampicin 
- epilepsy, such as carbamazepine, phenobarbital, phenytoin 
- symptoms of slightly low mood and mild anxiety: St. John's wort (a herbal medicine) 
- high cholesterol, such as rosuvastatin, fluvastatin, atorvastatin, pitavastatin 
- severe joint inflammation, severe cases of the skin disease psoriasis, and cancers: methotrexate 
- inflammatory bowel diseases: sulfasalazine </p>
<p>Your doctor may therefore change the dose of the medicines that you are taking. </p>
<p>Pregnancy, breast-feeding and fertility 
NUBEQA is not for use in women. 
This medicine could possibly have an effect on male fertility. 
Follow these advices during and for 1 week after stopping: 
- use a highly effective method of contraception to prevent pregnancy, if you are having sex with 
a woman who can become pregnant. 
- use a condom to protect the unborn baby, if you are having sex with a pregnant woman. </p>
<p>Driving and using machines 
This medicine is unlikely to affect your ability to drive and use machines. </p>
<p>NUBEQA contains lactose 
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor 
before taking this medicine. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take nubeqa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take nubeqa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor 
or pharmacist if you are not sure.  </p>
<p>The recommended dose is 
2 tablets 2 times daily </p>
<p>Your doctor may reduce your dose to 1 tablet 2 times daily, if you have problems with your liver or 
kidneys. </p>
<p>Method of use 
Swallow the tablets whole, take them with food and a glass of water. </p>
<p>Your doctor may also prescribe other medicines while you are taking NUBEQA. </p>
<p>If you take more NUBEQA than you should 
Continue the treatment with the next dose as scheduled. </p>
<p>If you forget to take NUBEQA 
Take your missed dose as soon as you remember before the next scheduled dose. Do not take a double 
dose to make up for 1 or more forgotten tablets. </p>
<p>If you stop taking NUBEQA 
Do not stop taking this medicine unless your doctor tells you to. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Side effects of NUBEQA occur with the following frequencies: </p>
<p>In patients with non-metastatic castration-resistant prostate cancer 
Very common side effects (may affect more than 1 in 10 people): 
- tiredness 
- blood tests showing reduced number of a white blood cell type called neutrophils 
- blood tests showing increased levels of substances produced by the liver: bilirubin, aspartate 
transaminase </p>
<p>Common side effects (may affect up to 1 in 10 people): 
- blockage of the arteries in the heart 
- heart failure 
- rash 
- pain in arms and legs 
- pain in muscles and bones 
- broken bones </p>
<p>In patients with metastatic hormone-sensitive prostate cancer 
Very common side effects (may affect more than 1 in 10 people): 
- high blood pressure 
- rash 
- blood tests showing reduced number of a white blood cell type called neutrophils 
- blood tests showing increased levels of substances produced by the liver: bilirubin, alanine 
transaminase and aspartate transaminase </p>
<p>Common side effects (may affect up to 1 in 10 people): 
- broken bones 
- breast enlargement in men </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects, you can help provide more information on the safety 
of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store nubeqa"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store nubeqa"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and on each blister after 
EXP. The expiry date refers to the last day of that month. </p>
<p>This medicine does not require any special storage conditions. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What NUBEQA contains 
The active substance is darolutamide. Each film-coated tablet contains 300 mg of darolutamide. 
The other ingredients are: 
- calcium hydrogen phosphate (E 341) 
- croscarmellose sodium 
- hypromellose 
- lactose monohydrate 
- macrogol (E 1521) 
- magnesium stearate (E 470b) 
- povidone (E 1201) 
- titanium dioxide (E 171) </p>
<p>See “NUBEQA contains lactose” in section 2 for more information. </p>
<p>What NUBEQA looks like and contents of the pack 
The film-coated tablets (tablets) are white to off-white, oval with a length of 16 mm and a width of 
8 mm. They are marked with “300” on one side, and “BAYER” on the other side. </p>
<p>Each carton contains: 
- 96 film-coated tablets consisting of 6 blisters or 
- 112 film-coated tablets consisting of 7 blisters </p>
<p>Each blister contains 16 film-coated tablets. </p>
<p>Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder 
Bayer AG 
51368 Leverkusen 
Germany </p>
<p>Manufacturer 
Orion Corporation, Orion Pharma 
24100 Salo 
Finland </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>België/Belgique/Belgien 
Bayer SA-NV 
Tél/Tel: +32-(0)2-5356Lietuva 
UAB Bayer 
Tel. +37 05 23 36 България 
Байер България ЕООД 
Tел.: +359 (0)2 424 72 Luxembourg/Luxemburg 
Bayer SA-NV 
Tél/Tel: +32-(0)2-535 63 Česká republika 
Bayer s.r.o. 
Tel: +420 266 101 Magyarország 
Bayer Hungária KFT 
Tel:+36 14 87-41 Danmark 
Bayer A/S 
Tlf: +45 45 23 50 Malta 
Alfred Gera and Sons Ltd. 
Tel: +35 621 44 62 Deutschland 
Bayer Vital GmbH 
Tel: +49 (0)214-30 513 Nederland 
Bayer B.V. 
Tel: +31-23-799 1Eesti 
Bayer OÜ 
Tel: +372 655 8Norge 
Bayer AS 
Tlf: +47 24 11 18 Ελλάδα 
Bayer Ελλάς ΑΒΕΕ 
Τηλ: +30 210-618 75 Österreich 
Bayer Austria Ges.m.b.H. 
Tel: +43-(0)1-711 46-0 
España 
Bayer Hispania S.L. 
Tel: +34-93-495 65 Polska 
Bayer Sp. z.o.o. 
Tel: +48 22 572 35 France 
Bayer HealthCare 
Tél (N° vert): +33-(0)800 87 54 Portugal 
Bayer Portugal, Lda. 
Tel: +351 21 416 42 Hrvatska 
Bayer d.o.o. 
Tel: +385-(0)1-6599 România 
SC Bayer s.r.l. 
Tel: +40 21 529 59 Ireland 
Bayer Limited 
Tel: +353 1 216 3Slovenija 
Bayer d. o. o. 
Tel: +386 1 58 14 Ísland 
Icepharma hf. 
Sími: +354 540 8Slovenská republika 
Bayer spol. s r.o. 
Tel. +421 2 59 21 31 Italia 
Bayer S.p.A. 
Tel: +39 02 397 Suomi/Finland 
Bayer Oy 
Puh/Tel: +358 20 785 Κύπρος 
NOVAGEM Limited 
Tηλ: +357 22 48 38 Sverige 
Bayer AB 
Tel: +46 (0) 8 580 223 Latvija 
SIA Bayer 
Tel: +371 67 84 55 United Kingdom (Northern Ireland) 
Bayer AG 
Tel: +44-(0)118 206 3 </p>
<p>This leaflet was last revised in </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      

